Leczenie objawów ze strony dolnych dróg moczowych u mężczyzn – wytyczne i praktyka Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2017
Słowa kluczowe:
objawy ze strony dolnych dróg moczowych, łagodny rozrost gruczołu krokowego, tamsulosyna
##plugins.themes.bootstrap3.article.main##
Abstrakt
Objawy ze strony dolnych dróg moczowych u mężczyzn to istotny problem kliniczny. Obecnie możemy zindywidualizować terapię w zależności od etiologii i objawów zgłaszanych przez pacjenta. Niestety, nadal często opieramy się na przyzwyczajeniach, nie optymalizując terapii. Celem poniższej pracy było zestawienie praktycznych aspektów codziennej pracy klinicznej dotyczącej objawów ze strony dolnych dróg moczowych u mężczyzn z obecnie obowiązującymi wytycznymi Europejskiego Towarzystwa Urologicznego na ten temat.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Ostrowski, A., & Drewa, T. (2017). Leczenie objawów ze strony dolnych dróg moczowych u mężczyzn – wytyczne i praktyka . Medycyna Faktów , 10(2(35), 103-109. Pobrano z https://www.journalsmededu.pl/index.php/jebm/article/view/2150
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Kirby R.S.: The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 2000; 56(5 supl. 1): 3-6.
2. Netto N.R. Jr, de Lima M.L., Netto M.R., D’Ancona C.A.: Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology 1999; 53(2): 314-316.
3. Yap T.L., Brown C., Cromwell D.A. et al.: The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures. BJU Int. 2009; 104(8): 1104-1108.
4. Brown C.T., Yap T., Cromwell D.A. et al.: Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ 2007; 334(7583): 25.
5. Flanigan R.C., Reda D.J., Wasson J.H. et al.: 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J. Urol. 1998; 160(1): 12-16; discussion 16-17.
6. Michel M.C., Vrydag W.: Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br. J. Pharmacol. 2006; 147 supl. 2: S88-119.
7. Djavan B., Marberger M.: A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 1999; 36(1): 1-13.
8. Sica D.A., Carter B., Cushman W., Hamm L.: Thiazide and loop diuretics. J. Clin. Hypertens. (Greenwich) 2011; 13(9): 639-643.
9. Djavan B., Chapple C., Milani S., Marberger M.: State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64(6): 1081-1088.
10. Chapple Ch.R., Al-Shukri S.H., Gattegno B. et al.: Tamsulosin Oral Controlled Absorption System (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study. Eur. Urol. Suppl. 2005b; 4: 33-44.
11. Neill M.G., Shahani R., Zlotta A.R.: Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. Ther. Clin. Risk Manag. 2008; 4(1): 11-18.
12. Michel M.C., Mehlburger L., Bressel H.U., Goepel M.: Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1998; 1(6): 332-335.
13. Andriole G., Bruchovsky N., Chung L.W. et al.: Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J. Urol. 2004; 172(4 Pt 1): 1399-1403.
14. Naslund M.J., Miner M.: A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin. Ther. 2007; 29(1): 17-25.
15. Nickel J.C., Gilling P., Tammela T.L. et al.: Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011; 108(3): 388-394.
16. McConnell J.D., Bruskewitz R., Walsh P. et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N. Engl. J. Med. 1998; 338(9): 557-563.
17. Donohue J.F., Sharma H., Abraham R. et al.: Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J. Urol. 2002; 168(5): 2024-2026.
18. Trost L., Saitz T.R., Hellstrom W.J.: Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review. Sex. Med. Rev. 2013; 1(1): 24-41.
19. Hsieh T.F., Yang Y.W., Lee S.S. et al.: Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One 2015; 10(3): e0119694.
20. Andriole G.L., Bostwick D.G., Brawley O.W. et al.: Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 2010; 362(13): 1192-1202.
21. Thompson I.M., Goodman P.J., Tangen C.M. et al.: The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003; 349(3): 215-224.
22. Roehrborn C.G., Siami P., Barkin J. et al.: The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 2010; 57(1): 123-131.
23. McConnell J.D., Roehrborn C.G., Bautista O.M. et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2003; 349(25): 2387-2398.
24. Kirby R.S., Roehrborn C., Boyle P. et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61(1): 119-126.
25. Lepor H., Williford W.O., Barry M.J. et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N. Engl. J. Med. 1996; 335(8): 533-539.
26. Barkin J., Guimarães M., Jacobi G. et al.: Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur. Urol. 2003; 44(4): 461-466.
27. Chess-Williams R., Chapple C.R., Yamanishi T. et al.: The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J. Auton. Pharmacol. 2001; 21(5-6): 243-248.
28. Matsui M., Motomura D., Karasawa H. et al.: Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc. Natl. Acad. Sci. U S A 2000; 97(17): 9579-9584.
29. Goldfischer E.R., Sand P.K., Thomas H., Peters-Gee J.: Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Neurourol. Urodyn. 2015; 34(1): 37-43.
30. Roehrborn C.G., Abrams P., Rovner E.S. et al.: Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006; 97(5): 1003-1006.
31. Kaplan S.A., Goldfischer E.R., Steers W.D. et al.: Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Aging Male 2010; 13(2): 100-107.
32. Abrams P., Kaplan S., De Koning Gans H.J., Millard R.: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J. Urol. 2006; 175(3 Pt 1): 999-1004; discussion 1004.
33. Nalliah S., Wg P., Masten Singh P.K. et al.: Comparison of efficacy and tolerability of pharmacological treatment for the overactive bladder in women: A network meta-analysis. Aust. Fam. Physician. 2017; 46(3): 139-144.
34. Li M.C., Wang Z.Y., Yang J. et al.: Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis. Asian. J. Androl. 2015; 17(1): 124-134.
35. Morelli A., Sarchielli E., Comeglio P. et al.: Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J. Sex. Med. 2011; 8(10): 2746-2760.
36. Giuliano F., Ückert S., Maggi M. et al.: The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur. Urol. 2013; 63(3): 506-516.
37. Vignozzi L., Gacci M., Cellai I. et al.: PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 2013; 73(13): 1391-1402.
38. Oelke M., Giuliano F., Mirone V. et al.: Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur. Urol. 2012; 61(5): 917-925.
39. Gacci M., Corona G., Salvi M. et al.: A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur. Urol. 2012; 61(5): 994-1003.
40. Brock G.B., McVary K.T., Roehrborn C.G. et al.: Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J. Urol. 2014; 191(2): 405-411.
41. Casabé A., Roehrborn C.G., Da Pozzo L.F. et al.: Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J. Urol. 2014; 191(3): 727-733.
42. Khullar V., Amarenco G., Angulo J.C. et al.: Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur. Urol. 2013; 63(2): 283-295.
43. Nitti V.W., Rosenberg S., Mitcheson D.H. et al.: Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J. Urol. 2013; 190(4): 1320-1327.
44. Kim J.C., Cho K.J., Lee J.G. et al.: Efficacy and Safety of Desmopressin Add-On Therapy for Men with Persistent Nocturia on alpha-Blocker Monotherapy for Lower Urinary Tract Symptoms: A Randomized, Double-Blind, Pla cebo Controlled Study. J. Urol. 2017; 197(2): 459-464.
45. Rembratt A., Riis A., Norgaard J.P.: Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol. Urodyn. 2006; 25(2): 105-109.
46. Weiss J.P., Herschorn S., Albei C.D., van der Meulen E.A.: Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J. Urol. 2013; 190(3): 965-972.
2. Netto N.R. Jr, de Lima M.L., Netto M.R., D’Ancona C.A.: Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology 1999; 53(2): 314-316.
3. Yap T.L., Brown C., Cromwell D.A. et al.: The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures. BJU Int. 2009; 104(8): 1104-1108.
4. Brown C.T., Yap T., Cromwell D.A. et al.: Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ 2007; 334(7583): 25.
5. Flanigan R.C., Reda D.J., Wasson J.H. et al.: 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J. Urol. 1998; 160(1): 12-16; discussion 16-17.
6. Michel M.C., Vrydag W.: Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br. J. Pharmacol. 2006; 147 supl. 2: S88-119.
7. Djavan B., Marberger M.: A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 1999; 36(1): 1-13.
8. Sica D.A., Carter B., Cushman W., Hamm L.: Thiazide and loop diuretics. J. Clin. Hypertens. (Greenwich) 2011; 13(9): 639-643.
9. Djavan B., Chapple C., Milani S., Marberger M.: State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64(6): 1081-1088.
10. Chapple Ch.R., Al-Shukri S.H., Gattegno B. et al.: Tamsulosin Oral Controlled Absorption System (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study. Eur. Urol. Suppl. 2005b; 4: 33-44.
11. Neill M.G., Shahani R., Zlotta A.R.: Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. Ther. Clin. Risk Manag. 2008; 4(1): 11-18.
12. Michel M.C., Mehlburger L., Bressel H.U., Goepel M.: Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1998; 1(6): 332-335.
13. Andriole G., Bruchovsky N., Chung L.W. et al.: Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J. Urol. 2004; 172(4 Pt 1): 1399-1403.
14. Naslund M.J., Miner M.: A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin. Ther. 2007; 29(1): 17-25.
15. Nickel J.C., Gilling P., Tammela T.L. et al.: Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011; 108(3): 388-394.
16. McConnell J.D., Bruskewitz R., Walsh P. et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N. Engl. J. Med. 1998; 338(9): 557-563.
17. Donohue J.F., Sharma H., Abraham R. et al.: Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J. Urol. 2002; 168(5): 2024-2026.
18. Trost L., Saitz T.R., Hellstrom W.J.: Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review. Sex. Med. Rev. 2013; 1(1): 24-41.
19. Hsieh T.F., Yang Y.W., Lee S.S. et al.: Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One 2015; 10(3): e0119694.
20. Andriole G.L., Bostwick D.G., Brawley O.W. et al.: Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 2010; 362(13): 1192-1202.
21. Thompson I.M., Goodman P.J., Tangen C.M. et al.: The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003; 349(3): 215-224.
22. Roehrborn C.G., Siami P., Barkin J. et al.: The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol. 2010; 57(1): 123-131.
23. McConnell J.D., Roehrborn C.G., Bautista O.M. et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2003; 349(25): 2387-2398.
24. Kirby R.S., Roehrborn C., Boyle P. et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61(1): 119-126.
25. Lepor H., Williford W.O., Barry M.J. et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N. Engl. J. Med. 1996; 335(8): 533-539.
26. Barkin J., Guimarães M., Jacobi G. et al.: Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur. Urol. 2003; 44(4): 461-466.
27. Chess-Williams R., Chapple C.R., Yamanishi T. et al.: The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J. Auton. Pharmacol. 2001; 21(5-6): 243-248.
28. Matsui M., Motomura D., Karasawa H. et al.: Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc. Natl. Acad. Sci. U S A 2000; 97(17): 9579-9584.
29. Goldfischer E.R., Sand P.K., Thomas H., Peters-Gee J.: Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Neurourol. Urodyn. 2015; 34(1): 37-43.
30. Roehrborn C.G., Abrams P., Rovner E.S. et al.: Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006; 97(5): 1003-1006.
31. Kaplan S.A., Goldfischer E.R., Steers W.D. et al.: Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Aging Male 2010; 13(2): 100-107.
32. Abrams P., Kaplan S., De Koning Gans H.J., Millard R.: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J. Urol. 2006; 175(3 Pt 1): 999-1004; discussion 1004.
33. Nalliah S., Wg P., Masten Singh P.K. et al.: Comparison of efficacy and tolerability of pharmacological treatment for the overactive bladder in women: A network meta-analysis. Aust. Fam. Physician. 2017; 46(3): 139-144.
34. Li M.C., Wang Z.Y., Yang J. et al.: Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis. Asian. J. Androl. 2015; 17(1): 124-134.
35. Morelli A., Sarchielli E., Comeglio P. et al.: Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J. Sex. Med. 2011; 8(10): 2746-2760.
36. Giuliano F., Ückert S., Maggi M. et al.: The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur. Urol. 2013; 63(3): 506-516.
37. Vignozzi L., Gacci M., Cellai I. et al.: PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 2013; 73(13): 1391-1402.
38. Oelke M., Giuliano F., Mirone V. et al.: Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur. Urol. 2012; 61(5): 917-925.
39. Gacci M., Corona G., Salvi M. et al.: A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur. Urol. 2012; 61(5): 994-1003.
40. Brock G.B., McVary K.T., Roehrborn C.G. et al.: Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J. Urol. 2014; 191(2): 405-411.
41. Casabé A., Roehrborn C.G., Da Pozzo L.F. et al.: Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J. Urol. 2014; 191(3): 727-733.
42. Khullar V., Amarenco G., Angulo J.C. et al.: Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur. Urol. 2013; 63(2): 283-295.
43. Nitti V.W., Rosenberg S., Mitcheson D.H. et al.: Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J. Urol. 2013; 190(4): 1320-1327.
44. Kim J.C., Cho K.J., Lee J.G. et al.: Efficacy and Safety of Desmopressin Add-On Therapy for Men with Persistent Nocturia on alpha-Blocker Monotherapy for Lower Urinary Tract Symptoms: A Randomized, Double-Blind, Pla cebo Controlled Study. J. Urol. 2017; 197(2): 459-464.
45. Rembratt A., Riis A., Norgaard J.P.: Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol. Urodyn. 2006; 25(2): 105-109.
46. Weiss J.P., Herschorn S., Albei C.D., van der Meulen E.A.: Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J. Urol. 2013; 190(3): 965-972.